LMI 070

Drug Profile

LMI 070

Alternative Names: LMI-070

Latest Information Update: 16 Dec 2016

Price : $50

At a glance

  • Originator Novartis
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Spinal muscular atrophy

Most Recent Events

  • 27 Oct 2014 Preclinical trials in Spinal muscular atrophy in Switzerland (PO)
  • 27 Oct 2014 Novartis plans a phase II trial for Spinal muscular atrophy (In infants) in Belgium, Denmark, Germany and Italy (NCT02268552)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top